Table 2.
Characteristics of individual patients.
| No. | Age(year) | Sex | ECOG PS | Cancer type | Sites of metastasis when on treatment | KRAS/BRAF mutation status | MMR or MSI status | Combining regimen | No. of cycles | Response |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 62 | F | 0 | Rectum | Abdomino-pelvic cavity | Wt | pMMR/MSS | Cam+Rego+XELOX | 17 | PR |
| 2 | 68 | F | 1 | Rectum | Liver, lung, kidney, peritoneal cavity, RPLN | Wt | pMMR/MSS | Cam+Rego+XELOX | 4 | PD |
| 3 | 45 | F | 1 | Right-sided colon | Peritoneal cavity, RPLN, abdominal aortic LN | KRAS Mt | pMMR/MSS | Cam+Rego+XELOX | 8 | SD |
| 4 | 70 | M | 0 | Right-sided colon | Liver, lung, peritoneal cavity | KRAS Mt | pMMR/MSS | Cam+Rego+XELOX | 15 | PR |
| 5 | 58 | M | 0 | Right-sided colon | Liver | Wt | pMMR/MSS | Cam+Rego+XELOX | 14 | PR |
| 6 | 55 | M | 0 | Rectum | Lung | Wt | pMMR/MSS | Cam+Rego+XELOX | 15 | PR |
| 7 | 53 | F | 0 | Rectum | Liver | KRAS Mt | pMMR/MSS | Cam+Bev+XELOX | 4 | PR |
| 8 | 64 | M | 0 | Right-sided colon | Liver, lung, peritoneal cavity | Unknown | Unknown | Cam+Bev+XELOX | 18 | PR |
| 9 | 86 | F | 2 | Right-sided colon | Abdomino-pelvic cavity | Unknown | Unknown | Cam+Bev+XELOX | 2 | SD |
| 10 | 78 | M | 0 | Left-sided colon | Liver | Wt | pMMR/MSS | Cam+Bev+XELOX | 4 | PR |
| 11 | 65 | M | 0 | Left-sided colon | Liver | Wt | pMMR/MSS | Cam+Bev+XELOX | 7 | PR |
| 12 | 64 | M | 0 | Rectum | Lung | Wt | pMMR/MSS | Cam+Bev+XELOX | 8 | PR |
| 13 | 69 | M | 0 | Left-sided colon | Peritoneum | KRAS Mt | pMMR/MSS | Cam+Bev+XELOX | 6 | PR |
| 14 | 70 | M | 1 | Rectum | Pelvic cavity | Unknown | pMMR/MSS | Cam+Bev+XELOX | 10 | SD |
| 15 | 66 | F | 0 | Left-sided colon | Liver | KRAS Mt | dMMR/MSI-H | Cam+Bev+XELOX | 14 | PR |
| 16 | 62 | F | 0 | Right-sided colon | Adrenal gland, peritoneal cavity, peritoneum, lymph nodes | Unknown | pMMR/MSS | Cam+Bev+XELOX | 6 | SD |
| 17 | 43 | F | 0 | Left-sided colon | Liver | Wt | pMMR/MSS | Cam+Bev+XELOX | 8 | PR |
| 18 | 55 | F | 1 | Right-sided colon | Liver, peritoneum, peritoneal cavity | Unknown | pMMR/MSS | Cam+Bev+XELOX | 12 | PR |
| 19 | 52 | M | 0 | Rectum | Lung | KRAS Mt | pMMR/MSS | Cam+Bev+XELOX | 8 | SD |
| 20 | 57 | F | 1 | Rectum | Liver, peritoneal cavity, bilateral ovarian | KRAS Mt | pMMR/MSS | Cam+Bev+XELOX | 11 | PR |
| 21 | 67 | M | 2 | Rectum | Liver, peritoneum | Unknown | Unknown | Cam+Bev+XELOX | 5 | PR |
| 22 | 63 | M | 0 | Left-sided colon | Liver, lymph nodes | KRAS Mt | pMMR/MSS | Cam+Bev+XELOX | 5 | PR |
| 23 | 54 | F | 1 | Rectum | Liver | Wt | pMMR/MSS | Cam+Bev+XELOX | 4 | PR |
| 24 | 77 | F | 1 | Rectum | Lung, bone, cervical and pelvic wall | Wt | pMMR/MSS | Cam+Bev+XELOX | 3 | PR |
| 25 | 76 | M | 1 | Left-sided colon | Abdominal wall, abdomino-pelvic cavity | Wt | pMMR/MSS | Cam+Bev+XELOX | 8 | SD |
ECOG PS, Eastern Cooperative Oncology Group performance status; F, female; M, male; Mt, mutant; Wt, wild-type; Cam, camrelizumab; Bev, bevacizumab; Rego, regorafenib; XELOX, capecitabine and oxaliplatin; PR, partial response; SD, stable disease; PD, progression of disease; RPLN, retroperitoneal lymph node.